R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Challenges and opportunities in the off-patent sector: the p...

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz.

R&D

How Pharmacogenomics may finally realise its promise

More than 60 percent of a

Digital

AI tissue analysis enables rapid discovery of drug candidate...

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient gr

R&D

Traditional approaches to growth in biopharma are no longer ...

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions.

R&D

Connecting EHR to clinical trials: How to embrace the promis...

We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding us back?

Market Access